share_log

Maxim Group Upgrades Agile Therapeutics to Buy, Announces $1 Price Target

Maxim Group Upgrades Agile Therapeutics to Buy, Announces $1 Price Target

Maxim Group 將敏捷療法升級爲收購,宣佈目標價爲1美元
Benzinga Real-time News ·  2022/07/26 08:14

Maxim Group analyst Naz Rahman upgrades Agile Therapeutics (NASDAQ:AGRX) from Hold to Buy and announces $1 price target.

Maxim集團分析師納茲·拉赫曼將Agile Therapeutics(納斯達克股票代碼:AGRX)從 “持有” 上調至 “買入”,並宣佈了1美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論